Programming the immunological properties of mRNA vaccines for cancer.

mRNA cancer vaccines can be programmed by tuning nucleoside chemistry, delivery, and dosing to balance four immunological axes and achieve durable, tumor-specific immunity.

• Why it matters: Current mRNA vaccine designs face competing risks—too little activation or too much immunopathology, tolerance, exhaustion, or systemic toxicity—limiting consistent efficacy in oncology trials.
• What they did: The work proposes a framework linking adjuvanticity vs immunopathology, immunogenicity vs tolerance, memory vs exhaustion, and beneficial vs maladaptive trained immunity, then maps design levers to antigen identity/decay, costimulation, cytokine tone, and innate stimulation.
• The result: It outlines design principles for positioning vaccines in an “optimal window” that supports durable, tumor-specific T and B cell responses while minimizing exhaustion, tolerance, and systemic toxicity.

AI summary of the abstract · may contain errors · not medical advice · read the paper.